share_log

Wedbush Reiterates Outperform on Immunome, Maintains $33 Price Target

Benzinga ·  Aug 13 21:06  · Ratings

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $33 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment